Exelixis/$EXEL
1D1W1MYTD1Y5YMAX
Capital at risk
About Exelixis
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
- Ticker
- $EXEL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,077
- Headquarters
- Alameda, United States
- Website
- www.exelixis.com
Exelixis Metrics
BasicAdvanced
$15B
18.52
$3.19
0.42
-
Price and volume
Market cap
$15B
Beta
0.42
52-week high
$59.72
52-week low
$33.76
Average daily volume
2.5M
Financial strength
Current ratio
3.456
Quick ratio
3.244
Long term debt to equity
8.999
Total debt to equity
8.999
Profitability
EBITDA (TTM)
1,020.321
Gross margin (TTM)
96.48%
Net profit margin (TTM)
35.33%
Operating margin (TTM)
40.72%
Effective tax rate (TTM)
16.89%
Revenue per employee (TTM)
$2,260,000
Management effectiveness
Return on assets (TTM)
23.97%
Return on equity (TTM)
44.39%
Valuation
Price to earnings (TTM)
18.523
Price to revenue (TTM)
6.323
Price to book
7.97
Price to tangible book (TTM)
8.25
Price to free cash flow (TTM)
13.298
Free cash flow yield (TTM)
7.52%
Free cash flow per share (TTM)
4.437
Growth
Revenue change (TTM)
9.23%
Earnings per share change (TTM)
53.41%
3-year revenue growth (CAGR)
12.42%
10-year revenue growth (CAGR)
42.32%
3-year earnings per share growth (CAGR)
85.25%
10-year earnings per share growth (CAGR)
14.78%
What the Analysts think about Exelixis
Analyst ratings (Buy, Hold, Sell) for Exelixis stock.
Analyst projections of the future price of Exelixis stock.
Bulls say / Bears say
Total revenues for Q2 2026 were $628.7 million, up from $568.3 million in Q2 2025, reflecting double-digit year-over-year growth driven by strong cabozantinib sales and royalties (Exelixis Press Release (Exelixis))
The pipeline features multiple near-term catalysts including anticipated topline results from the STELLAR-304 trial in H2 2026 and an FDA PDUFA date of December 3, 2026 for the zanzalintinib/atezolizumab metastatic CRC NDA, providing clear milestones to drive value (Exelixis Press Release (Exelixis))
The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026 for the zanzalintinib + atezolizumab NDA, and Exelixis acknowledges that regulatory unpredictability could delay or derail approval for its next potential franchise molecule (Exelixis Press Release (Exelixis)
Multiple ANDAs and 505(b)(2) NDAs filed by MSN, Teva, Cipla, Azurity, Handa, and Accord seek approval of generic cabozantinib, which, if successful, could introduce lower-cost competitors and materially erode Exelixis’ cabozantinib franchise revenue (Exelixis Form 10-K (Exelixis), SEC Filing))
Government authorities, including CMS under the Inflation Reduction Act, are increasingly empowered to negotiate drug prices and impose significant rebates or penalties, which could lower average selling prices of CABOMETYX and COMETRIQ and pressure Exelixis’ profitability (Exelixis Form 10-K (Exelixis), (Exelixis))
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
Exelixis Financial Performance
Revenues and expenses
Exelixis Earnings Performance
Company profitability
Upcoming events
No upcoming events
Exelixis News
AllArticlesVideos
Funds containing Exelixis
AllUSDEURGBP
Fund name | Fund size | $EXEL weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 1.43% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.43% |
iShares Healthcare Innovation£DRDR | £1B | 1.43% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 1.00% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 1.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.